When is a stem cell transplant necessary? Discover the specific blood cancers (Leukemia, Lymphoma) and genetic disorders treated at Liv Hospital’s advanced hematology center.
Send us all your questions or requests, and our expert team will assist you.
Stem Cell Transplant Conditions and Indications
A stem cell transplant is a powerful, often curative treatment, but it is not suitable for every patient or every condition. It is a major medical procedure reserved for specific diseases where the potential for a cure or long-term remission outweighs the risks. At Liv Hospital, our multidisciplinary tumor board evaluates every case individually to determine if a transplant is the right path forward.
For international patients, understanding the specific indications the medical reasons to perform a transplant is the first step. Generally, a transplant is recommended when the bone marrow has failed, or when a blood cancer is aggressive, has returned after treatment (relapsed), or has a high risk of returning (high-risk features).
Blood cancers are the most common reason for a stem cell transplant. However, the type of transplant (Autologous vs. Allogeneic) depends on the specific disease.
Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) are aggressive cancers that start in the bone marrow.
Chronic Myeloid Leukemia (CML) is now often managed with targeted oral therapies (TKIs), but a transplant remains a curative option for patients who develop resistance to these drugs or progress to a “blast crisis.”
For Hodgkin Lymphoma and Non-Hodgkin Lymphoma (NHL), a transplant is typically indicated if the disease returns (relapsed) after initial chemotherapy or is “refractory” (does not respond).
Indication: An autologous transplant is the standard “second-line” treatment for relapsed Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma.
Multiple Myeloma is a cancer of the plasma cells.
Indication: An autologous transplant is considered the standard of care for eligible, newly diagnosed patients. While not always curative, it significantly extends survival and the period of remission.
The indications for a hematopoietic stem cell transplant (HSCT) are broadly categorized into two groups: malignant (cancerous) diseases and non-malignant (benign or genetic) disorders.
In malignant diseases, the transplant allows for the use of high-dose chemotherapy to kill cancer cells, followed by a “rescue” with new stem cells. In allogeneic transplants (using a donor), it also provides a new immune system to fight the cancer. In non-malignant diseases, the goal is to replace a faulty bone marrow factory with a healthy one.
Yes. One of the most remarkable advances in hematology is the ability to cure lifelong genetic disorders.
Having a condition listed above does not automatically make a patient a candidate for transplant. The patient’s body must be strong enough to withstand the “conditioning” chemotherapy. At Liv Hospital, we use rigorous international criteria to ensure safety:
For international patients, we request recent medical reports to perform a “pre-eligibility” assessment before travel.
In some cases, time is critical.
Liv Hospital’s International Patient Center prioritizes these cases, expediting the donor search (HLA typing) and visa processes to start treatment immediately.
Send us all your questions or requests, and our expert team will assist you.
“Stage 4” is a term usually used for solid tumors. For blood cancers, we look at “risk stratification.” A transplant can cure “high-risk” or advanced blood cancers (like leukemia or lymphoma) that have spread throughout the bone marrow and blood.
Generally, no. Stem cell transplants are primarily for blood and immune system cancers. However, they are sometimes used for Testicular Cancer (germ cell tumors) and certain childhood cancers like Neuroblastoma.
This is a common concern. Only about 30% of patients have a matched sibling. For the rest, Liv Hospital utilizes the global bone marrow registry (over 30 million donors) and advanced “Haploidentical” (half-match) protocols, allowing parents or children to be donors.
Yes, in specialized centers. Patients with HIV who have well-controlled viral loads can undergo autologous or allogeneic transplants for blood cancers (like lymphoma) with careful monitoring.
While an autologous transplant is the gold standard and can provide years of remission, Multiple Myeloma is often considered a chronic, manageable disease rather than “curable” in the traditional sense. However, new “tandem” transplants and maintenance therapies are pushing survival rates longer than ever.
Your Comparison List (you must select at least 2 packages)
